Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Becker

Showing results (231-240 of 274) with videos related to

Pageof 28
Sort By:
The Journal of Infectious Diseases|April 29, 2017
Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging CoronavirusesAnindya Siddharta, Stephanie Pfaender, Nathalie Jane Vielle, et al.
Iscience|August 16, 2024
Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approachLeonie M Weskamm, Paulina Tarnow, Charlotte Harms, et al.
Nature Communications|January 9, 2026
Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adultsLeonie Mayer, Anahita Fathi, Hanna-Marie Weichel, et al.
The Journal of Infectious Diseases|November 20, 2018
Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in HumansJoseph H Poetsch, Christine Dahlke, Madeleine E Zinser, et al.
Immunity|November 13, 2012
Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumorsPhilipp Yu, Wolger Lübben, Heike Slomka, et al.
Antiviral Research|February 12, 2018
The molecular tweezer CLR01 inhibits Ebola and Zika virus infectionAnnika E Röcker, Janis A Müller, Erik Dietzel, et al.
The Lancet. Infectious Diseases|August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
Plos One|November 21, 2017
Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumoniaKristina Dietert, Birgitt Gutbier, Sandra M Wienhold, et al.
Ebiomedicine|April 25, 2017
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV ImmunizationChristine Dahlke, Rahel Kasonta, Sebastian Lunemann, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2018
Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinovirusesDaniel P Potaczek, Sebastian D Unger, Nan Zhang, et al.
Pageof 28

Showing results (231-240 of 274) with videos related to

Sort By:
Pageof 28
The Journal of Infectious Diseases|April 29, 2017
Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging CoronavirusesAnindya Siddharta, Stephanie Pfaender, Nathalie Jane Vielle, et al.
Iscience|August 16, 2024
Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approachLeonie M Weskamm, Paulina Tarnow, Charlotte Harms, et al.
Nature Communications|January 9, 2026
Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adultsLeonie Mayer, Anahita Fathi, Hanna-Marie Weichel, et al.
The Journal of Infectious Diseases|November 20, 2018
Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in HumansJoseph H Poetsch, Christine Dahlke, Madeleine E Zinser, et al.
Immunity|November 13, 2012
Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumorsPhilipp Yu, Wolger Lübben, Heike Slomka, et al.
Antiviral Research|February 12, 2018
The molecular tweezer CLR01 inhibits Ebola and Zika virus infectionAnnika E Röcker, Janis A Müller, Erik Dietzel, et al.
The Lancet. Infectious Diseases|August 8, 2015
The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trialAngela Huttner, Julie-Anne Dayer, Sabine Yerly, et al.
Plos One|November 21, 2017
Spectrum of pathogen- and model-specific histopathologies in mouse models of acute pneumoniaKristina Dietert, Birgitt Gutbier, Sandra M Wienhold, et al.
Ebiomedicine|April 25, 2017
Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV ImmunizationChristine Dahlke, Rahel Kasonta, Sebastian Lunemann, et al.
The Journal of Allergy and Clinical Immunology|August 17, 2018
Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinovirusesDaniel P Potaczek, Sebastian D Unger, Nan Zhang, et al.
Pageof 28